Skip to content
Search

Latest Stories

Galen launches innovative medical food for PKU patients

Pharmaceutical firm Galen on Thursday launched an innovative medical food for people living with the rare, inherited metabolic disorder, phenylketonuria (PKU).

The PKU Easy Microtabs is an alternative to other protein substitutes on the market and will help patients from age 8 to manage the condition and consume the protein they need each day.


PKU Easy Microtabs are small coated microtabs containing non-Phe amino acids. They are swallowed with liquid or eaten with cold foods, such as jam or fruit puree.

Approximately 70 babies each year are born with PKU in the UK. The inherited disorder prevents the body from breaking down the proteins in foods to amino acids and if unmanaged, can lead to brain damage.

First launched by POA Pharma across Scandinavia in 2011, PKU Easy Microtabs was not available to UK patients via NHS until now. In January, Galen has announced the completion of its acquisition and takeover of POA Pharma.

Alongside its wider product portfolio, the move was intended to expand access to the company’s innovative nutritional therapies for people with PKU.

Dr Dennise Broderick, President & Managing Director at Galen, said: "Within one month of the completion of our acquisition of POA Pharma we are delighted to be able to bring this important new dietary management option to the 6,000 plus patients living with PKU across the UK.

"This is a condition that patients have to think about every single day of their lives to ensure they have the right levels of protein to function correctly. Portability, taste and digestion of medical foods are all important considerations that we are proud to have addressed for the community with our novel microtabs."

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less